The Hockey Mom Foundation is an all volunteer organization that honors Hockey Moms everywhere by raising funds to make one time foundational donations to non-profits focused on furthering cancer research, and the care of cancer patients.
Registration is Open for the
Friday, September 25, 2026, Glen Oak Golf Club, East Amherst, NY
Your generosity over the years has enabled so much toward cancer care and research.
Our latest grant was on December 29th, 2025 towards Car T research at Roswell. We contributed to Car T a couple of years ago in conjunction with the Margaret Weber Foundation and this line of research is very promising. December's $25,000 grant is to Adult and Pediatric Sarcoma Clinical Trials - see additional details below.
Additional information on the amazing research: CAR T-cell Therapy
Thanks to the generosity of our donors, friends, board, and volunteers, the HMF had the good fortune of providing grants to two cancer care/research programs at the close of 2024! Our 2025 donations total $45,000.
We granted $25,000 to Roswell Park Comprehensive Cancer Center for their Pediatric Palliative Care Partnership with Oishei Children's Hospital Pediatric Cancer and Blood Disorder Program. This program will support pediatric patients and families with a dedicated palliative care physician and advanced practice provider, aiming for improved pain and symptom management as well as optimized care coordination between palliative care,
primary medical, and psychosocial teams
Pictured, we presented Cleveland Clinic Lerner Research Institute a $20,000 grant. Masahiro Hitomi, MD, PhD,
and his collaborators are establishing a novel therapeutic sensitivity array using patient-derived cancer cells
to assist in treatment selection for patients with sarcoma, a rare type of tumor that develops in bone and
soft tissue. They have collected sarcoma cells to determine patient-specific anticancer drug sensitivity.
Testing various cell culture methods, the team aims to prepare a cell population that best represents
the tumor of the patient and establish quantitative measures to determine therapeutic sensitivity of
these cells. When established, this approach will provide data to reflect cancer cell susceptibility which
would minimize the chance of trial-and-error attempts, the drawback of current cancer treatment.
Thanks to the generosity of our donors, friends, board, and volunteers, the HMF had the good fortune of providing grants to two cancer care/research programs at the close of 2024! Our 2025 donations total $45,000.
We granted $25,000 to Roswell Park Comprehensive Cancer Center for their Pediatric Palliative Care Partnership with Oishei Children's Hospital Pediatric Cancer and Blood Disorder Program. This program will support pediatric patients and families with a dedicated palliative care physician and advanced practice provider, aiming for improved pain and symptom management as well as optimized care coordination between palliative care,
primary medical, and psychosocial teams
Pictured, we presented Cleveland Clinic Lerner Research Institute a $20,000 grant. Masahiro Hitomi, MD, PhD,
and his collaborators are establishing a novel therapeutic sensitivity array using patient-derived cancer cells
to assist in treatment selection for patients with sarcoma, a rare type of tumor that develops in bone and
soft tissue. They have collected sarcoma cells to determine patient-specific anticancer drug sensitivity.
Testing various cell culture methods, the team aims to prepare a cell population that best represents
the tumor of the patient and establish quantitative measures to determine therapeutic sensitivity of
these cells. When established, this approach will provide data to reflect cancer cell susceptibility which
would minimize the chance of trial-and-error attempts, the drawback of current cancer treatment.
December 2023 grant of $25,000 for Car T-cell research at Roswell Park Cancer Institute
The Hockey Mom foundation represented the generosity of our donors by presenting a $25,000 check to Amanda Berg of the Roswell Park Alliance Foundation for a promising CAR T-cell therapy clinical trial. With therapy improvements in survival rates for patients with blood cancers, the team at Roswell Park is shifting focus to using their technology and discoveries to study CAR T-cell therapy on solid tumors like breast, lung, pediatrics, prostate and more. Renier Brentjens, MD, PhD is actively working on two clinical trials which look to improve CAR T-cell therapy. Those trials are in very early stages, but could bring about groundbreaking changes to the way cancer is treated.
